Genasys Inc. (NASDAQ:GNSS – Free Report) – Roth Capital dropped their FY2024 earnings estimates for shares of Genasys in a report released on Thursday, September 19th. Roth Capital analyst S. Searle now anticipates that the company will post earnings of ($0.58) per share for the year, down from their previous estimate of ($0.57). The consensus estimate for Genasys’ current full-year earnings is ($0.57) per share. Roth Capital also issued estimates for Genasys’ Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.18) EPS and FY2026 earnings at $0.17 EPS.
Genasys (NASDAQ:GNSS – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $7.17 million during the quarter, compared to analysts’ expectations of $7.48 million. Genasys had a negative return on equity of 66.93% and a negative net margin of 108.72%. During the same period in the previous year, the firm posted ($0.04) earnings per share.
Read Our Latest Stock Report on GNSS
Genasys Stock Down 0.3 %
GNSS stock opened at $3.45 on Monday. The stock has a market capitalization of $153.86 million, a P/E ratio of -5.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.98 and a current ratio of 2.58. Genasys has a one year low of $1.51 and a one year high of $3.58. The company has a 50 day moving average price of $2.87 and a two-hundred day moving average price of $2.36.
Insider Activity
In other Genasys news, Director Mark Culhane purchased 17,587 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was purchased at an average cost of $2.65 per share, with a total value of $46,605.55. Following the transaction, the director now owns 37,587 shares in the company, valued at $99,605.55. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.50% of the company’s stock.
Institutional Trading of Genasys
A number of institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. boosted its position in Genasys by 49.4% during the 4th quarter. Victory Capital Management Inc. now owns 30,885 shares of the company’s stock worth $63,000 after purchasing an additional 10,212 shares during the period. BOKF NA boosted its position in Genasys by 54.8% during the 1st quarter. BOKF NA now owns 84,700 shares of the company’s stock worth $197,000 after purchasing an additional 30,000 shares during the period. Pacific Ridge Capital Partners LLC boosted its position in Genasys by 4.2% during the 4th quarter. Pacific Ridge Capital Partners LLC now owns 1,054,481 shares of the company’s stock worth $2,141,000 after purchasing an additional 42,703 shares during the period. Cutter & CO Brokerage Inc. lifted its holdings in Genasys by 129.1% in the 1st quarter. Cutter & CO Brokerage Inc. now owns 120,500 shares of the company’s stock worth $286,000 after buying an additional 67,900 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Genasys by 14.0% in the 1st quarter. Vanguard Group Inc. now owns 1,932,185 shares of the company’s stock worth $4,579,000 after buying an additional 237,871 shares in the last quarter. 40.04% of the stock is owned by hedge funds and other institutional investors.
Genasys Company Profile
Genasys Inc engages in the design, development, and commercialization of critical communications hardware and software solutions to alert, inform, and protect people principally in North and South America, Europe, the Middle East, Asia, and internationally. The company operates through two segments, Hardware and Software.
Featured Stories
- Five stocks we like better than Genasys
- Pros And Cons Of Monthly Dividend Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Which Wall Street Analysts are the Most Accurate?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Overbought Stocks Explained: Should You Trade Them?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Genasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genasys and related companies with MarketBeat.com's FREE daily email newsletter.